This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuzucu, C.
Right arrow Articles by Hadley, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuzucu, C.
Right arrow Articles by Hadley, S.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, March 2004, p. 1224-1227, Vol. 42, No. 3
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.3.1224-1227.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Comparison of the Semisolid Agar Antifungal Susceptibility Test with the NCCLS M38-P Broth Microdilution Test for Screening of Filamentous Fungi

Cigdem Kuzucu,1 Barbara Rapino,2 Laura McDermott,2 and Susan Hadley2*

Inonu University Faculty of Medicine, Malatya, Turkey,1 Tufts University School of Medicine, Boston, Massachusetts2

Received 29 April 2003/ Returned for modification 3 July 2003/ Accepted 3 November 2003

Antifungal susceptibility testing of pathogenic molds is being developed. A simple screening semisolid agar antifungal susceptibility (SAAS) test accurately measures susceptibilities of yeasts. The performance of the SAAS screening test for filamentous fungi was assessed by comparing MICs of four antifungals (amphotericin B [AMB], AMB lipid complex [ABEL], itraconazole [ITZ], and posaconazole [POS]) for 54 clinical mold isolates with the results of the National Committee for Clinical Laboratory Standards (NCCLS) proposed broth microdilution method (M38-P). The SAAS test utilized inocula stabbed into tubes of 0.5% semisolid heart infusion agar. In both tests MICs were read after incubation at 35°C for 48 h. The isolates tested were Aspergillus fumigatus, Aspergillus niger, Aspergillus flavus, other Aspergillus spp., Fusarium spp., Penicillium sp., Mucor sp., Scedosporium prolificans, Trichophyton sp., and an unidentified dematiaceous mold. Concordance of test results was determined as the percent agreement of MICs ± 1 dilution. The overall agreement between the tests for each drug was as follows: AMB, 94%; ABEL, 83%; ITZ, 94%; POS, 94%. For the Aspergillus spp., all but one were susceptible to ITZ by SAAS test; all were susceptible to POS (MIC range, 0.25 to 4 µg/ml). Three of six non-Aspergillus molds that were resistant to AMB and ABEL by SAAS (MIC >= 2 µg/ml) were also resistant by the NCCLS test. The SAAS test compared favorably to the NCCLS broth microdilution test for molds, and most of the clinical isolates tested were susceptible to all four drugs.

* Corresponding author. Mailing address: Division of Geographic Medicine and Infectious Diseases, Tufts-New England Medical Center, Box 41, 750 Washington St., Boston, MA 02111. Phone: (617) 636-1567. Fax: (617) 636-8525. E-mail: shadley{at}tufts-nemc.org.

Journal of Clinical Microbiology, March 2004, p. 1224-1227, Vol. 42, No. 3
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.3.1224-1227.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»